Legal & General Group
NVIV

Legal & General Group’s InVivo Therapeutics Holdings Corp NVIV Stock Holding History

Legal & General Group’s Portfolio NVIV Stock Details NVIV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-27
Closed -$1.36M – 3339
2017
Q2 		$1.36M Buy
27
+26
+2,600% +$1.42M ﹤0.01% 1719
2017
Q1 		$45K Hold
1
– – ﹤0.01% 2893
2016
Q4 		$50K Buy
+1
New +$89.4K ﹤0.01% 2892
2016
Q3 		– Hold
0
– – – 2640
2016
Q2 		– Hold
0
– – – 2688

Other funds holding NVIV

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ICM
IMS Capital Management Portland, Oregon $217M AUM 18.69% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
WF
Welch & Forbes Boston, Massachusetts $7.73B AUM 14.94% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
RJA
Raymond James & Associates St Petersburg, Florida $164B AUM 33.91% 1-Year Est. Return

Legal & General Group's NVIV Position: Q3 2017 in Review

Legal & General Group sold out of InVivo Therapeutics Holdings Corp (NVIV) in Q3 2017, closing a stake of 27 shares — an estimated $1.36M sold.

Legal & General Group first reported a position in NVIV in Q4 2016 and held it in 3 quarters. The position peaked at $1.36M in Q2 2017. 33 funds tracked by Wall St. Rank hold NVIV as of Q3 2017.

  • Legal & General Group reported no remaining InVivo Therapeutics Holdings Corp position as of Q3 2017 after selling out during the quarter.
  • Legal & General Group sold 27 InVivo Therapeutics Holdings Corp shares in Q3 2017, an estimated $1.36M.
  • Legal & General Group first reported a position in InVivo Therapeutics Holdings Corp in Q4 2016 and held it in 3 quarters.
  • Legal & General Group's InVivo Therapeutics Holdings Corp position peaked at $1.36M in Q2 2017.
  • 33 funds tracked by Wall St. Rank held InVivo Therapeutics Holdings Corp as of Q3 2017.

Based on Legal & General Group's 13F filing for Q3 2017, filed 9 Nov 2017.